Company / Return on Equity (ROE)
Decoy Therapeutics Inc. Return on Equity (ROE) History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-33.0%
FY2022
5-year range
-135.7% / -33.0%
FY2018-FY2022
Trend
+0.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Decoy Therapeutics Inc. reports negative total equity of -33.0% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-33.0% in FY2022 with a 5-year CAGR of -1.4%.
Improved from -65.5% to -33.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -1.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, return on equity (roe) increased 0.6% year-over-year.
- Peak return on equity (roe) was recorded in FY2017.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | -33.0% | +0.6% |
| FY2021 | -33.2% | +49.4% |
| FY2020 | -65.5% | - |
| FY2019 | - | - |
| FY2018 | -135.7% | -329.3% |
| FY2017 | -31.6% | - |
| FY2016 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026